Benjamin Brucker, MD
Urology · New York, NYNPI 1235295619
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by AbbVie at 37.4% of the total. 2025 is the largest year on record at $80,464, 4.6 times the $17,542 reported in 2019. Among urology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 473 payments — averaging $770.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$136K
- Sumitomo Pharma America, Inc.$83K
- Antares Pharma, Inc.$38K
- Medtronic$27K
- Boston Scientific$19K
- Axonics, Inc.$19K
- plus $41K from 21 others
Across 53 payments — averaging $4506.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$177K
- Sumitomo Pharma America, Inc.$52K
- Provepharm Inc.$4K
- Boston Scientific$4K
- Ipsen Pharma SAS$2K
- Medtronic$976
What the payments were for
- Consulting fees$124,69834%
- Speaking & faculty fees$186,65751%
- Travel & lodging$41,97712%
- Food & beverage$11,1403%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 221 | $136,481 |
| Sumitomo Pharma America, Inc. | 59 | $82,989 |
| Antares Pharma, Inc. | 26 | $38,409 |
| Medtronic(2 entities) | 49 | $27,245 |
| Boston Scientific | 17 | $19,331 |
| Axonics, Inc. | 21 | $18,615 |
| Urovant Sciences Inc | 18 | $17,952 |
| Palette Life Sciences, Inc. | 9 | $10,711 |
| Purdue Pharma L.p. | 1 | $6,600 |
| Provepharm Inc. | 4 | $4,557 |
| Procept Biorobotics Corporation | 3 | $344 |
| Coloplast | 5 | $224 |
| Astellas Pharma US Inc | 11 | $200 |
| Teleflex LLC | 2 | $167 |
| Urogen Pharma, Inc. | 5 | $119 |
| Hollister Incorporated | 5 | $109 |
| Olympus America Inc. | 1 | $108 |
| Pfizer | 5 | $86 |
| Dentsply IH Inc. | 3 | $48 |
| Johnson & Johnson | 1 | $31 |
| Civco Medical Instruments | 1 | $26 |
| Dentsply IH AB | 1 | $25 |
| Novo Nordisk | 1 | $24 |
| Immunitybio, Inc. | 1 | $22 |
| Mission Pharmacal Company | 1 | $20 |
| ABC Home Medical Supply, Inc. | 1 | $17 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$126,934
- GEMTESA$100,428
- NOCDURNA$38,235
- Axonics$36,740
- BLUDIGO$4,550
- INTERSTIM$1,393
- Solesta$987
- ALTAVIVA$593
- AquaBeam Robotic System$269
- Bulkamid$265
- Advantage System$147
- UPSYLON$136
- UroLift$128
- ALTIS$126
- iTIND System$108
How this compares
$364,478 in reported general payments places this provider in the 95th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 299 | $209,211 |
| GemtesaVibegron | 174 | $113,728 |
| Mirabegron ErMirabegron | 28 | $13,051 |
| Estradiol | 167 | $11,896 |
| Tamsulosin Hcl | 126 | $2,485 |
| Solifenacin Succinate | 39 | $2,448 |
| Tolterodine Tartrate ErTolterodine Tartrate | 23 | $1,844 |
| Methenamine Hippurate | 33 | $1,765 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 84 | $1,399 |
| Finasteride | 66 | $1,236 |
| Oxybutynin Chloride ErOxybutynin Chloride | 16 | $417 |
| NitrofurantoinNitrofurantoin Macrocrystal | 21 | $277 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 21 | $216 |
| Trospium Chloride | 15 | $192 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $200 | $209,211299 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $82,989 | $113,728174 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 urology providers in New York.
Other urology in New York
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Kyrollis AttallaNew York$381K
- Ketan BadaniNew York$285K
- Michael GrassoNew York$284K
- Mantu GuptaNew York$229K
- Robin SmithNew York$215K
- Jean-Francois EidNew York$146K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.